{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T13:37:31Z","timestamp":1776433051279,"version":"3.51.2"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.canlet.2012.05.003","type":"journal-article","created":{"date-parts":[[2012,5,8]],"date-time":"2012-05-08T22:15:32Z","timestamp":1336515332000},"page":"83-90","source":"Crossref","is-referenced-by-count":43,"title":["Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells"],"prefix":"10.1016","volume":"324","author":[{"given":"Eva","family":"Juengel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Dauselt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmina","family":"Makarevi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Wiesner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Tsaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Bartsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Haferkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman A.","family":"Blaheta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2012.05.003_b0005","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ejca.2011.02.014","article-title":"Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma","volume":"47","author":"Porta","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2012.05.003_b0010","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/j.1464-410X.2011.10629.x","article-title":"Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials","volume":"108","author":"Coppin","year":"2011","journal-title":"BJU Int."},{"key":"10.1016\/j.canlet.2012.05.003_b0015","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.canlet.2012.05.003_b0020","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors","volume":"116","author":"Motzer","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2012.05.003_b0025","doi-asserted-by":"crossref","first-page":"369","DOI":"10.7150\/jca.2.369","article-title":"Biology of metastatic renal cell carcinoma","volume":"2","author":"Milella","year":"2011","journal-title":"J. Cancer"},{"key":"10.1016\/j.canlet.2012.05.003_b0030","doi-asserted-by":"crossref","first-page":"e25192","DOI":"10.1371\/journal.pone.0025192","article-title":"Anticancer effects of 15d-prostaglandin-J2 in wild-type and doxorubicin-resistant ovarian cancer cells: novel actions on SIRT1 and HDAC","volume":"6","author":"de Jong","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.canlet.2012.05.003_b0035","doi-asserted-by":"crossref","first-page":"4412","DOI":"10.1158\/0008-5472.CAN-10-4111","article-title":"HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer","volume":"71","author":"Stronach","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2012.05.003_b0040","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/1471-2407-9-161","article-title":"Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells","volume":"9","author":"Juengel","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2012.05.003_b0045","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1111\/j.1582-4934.2008.00436.x","article-title":"The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo","volume":"13","author":"Jones","year":"2009","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.canlet.2012.05.003_b0050","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ccr.2006.07.003","article-title":"Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin","volume":"10","author":"Phung","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2012.05.003_b0055","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ccr.2006.07.013","article-title":"Intracellular signaling in tumor and endothelial cells: The expected and, yet again, the unexpected","volume":"10","author":"Stoeltzing","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2012.05.003_b0060","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1093\/carcin\/bgr021","article-title":"2\u2032-hydroxyflavanone inhibits proliferation, tumor vascularization and promotes normal differentiation in VHL-mutant renal cell carcinoma","volume":"32","author":"Nagaprashantha","year":"2011","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.canlet.2012.05.003_b0065","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.canlet.2011.08.026","article-title":"The cdk1-cyclin B complex is involved in everolimus triggered resistance in the PC3 prostate cancer cell line","volume":"313","author":"Tsaur","year":"2011","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2012.05.003_b0070","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/carcin\/bgq249","article-title":"L1-CAM expression in ccRCC correlates with shorter patients survival times and confers chemoresistance in renal cell carcinoma cells","volume":"32","author":"Doberstein","year":"2011","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.canlet.2012.05.003_b0075","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1158\/1078-0432.CCR-09-3022","article-title":"The efficacy of the novel dual PI3-kinase\/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma","volume":"16","author":"Cho","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2012.05.003_b0080","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1586\/erm.09.8","article-title":"MTOR in renal cell cancer: modulator of tumor biology and therapeutic target","volume":"9","author":"Wysocki","year":"2009","journal-title":"Expert Rev. Mol. Diagn."},{"key":"10.1016\/j.canlet.2012.05.003_b0085","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/sj.bjc.6604636","article-title":"MTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work","volume":"99","author":"Le Tourneau","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2012.05.003_b0090","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.ejca.2011.01.003","article-title":"Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001","volume":"47","author":"Kuo","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2012.05.003_b0095","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/sj.bjc.6605479","article-title":"Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells","volume":"102","author":"Johnson","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2012.05.003_b0100","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1038\/onc.2010.154","article-title":"Therapeutic CDK4\/6 inhibition in breast cancer: key mechanisms of response and failure","volume":"29","author":"Dean","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2012.05.003_b0105","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/bjc.2011.452","article-title":"E\/N-cadherin switch mediates cancer progression via TGF-\u03b2-induced epithelial-to-mesenchymal transition in extrahepatic cholangiocarcinoma","volume":"105","author":"Araki","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2012.05.003_b0110","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.cellsig.2007.12.024","article-title":"PTPRK negatively regulates transcriptional activity of wild type and mutated oncogenic beta-catenin and affects membrane distribution of beta-catenin\/E-cadherin complexes in cancer cells","volume":"20","author":"Novellino","year":"2008","journal-title":"Cell. Signal."},{"key":"10.1016\/j.canlet.2012.05.003_b0115","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/modpathol.3800990","article-title":"Frequent accumulation of nuclear E-cadherin and alterations in the Wnt signaling pathway in esophageal squamous cell carcinomas","volume":"21","author":"Salahshor","year":"2008","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.canlet.2012.05.003_b0120","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1038\/labinvest.3700684","article-title":"Nuclear E-cadherin and VHL immunoreactivity are prognostic indicators of clear-cell renal cell carcinoma","volume":"87","author":"Gervais","year":"2007","journal-title":"Lab. Invest."},{"key":"10.1016\/j.canlet.2012.05.003_b0125","doi-asserted-by":"crossref","first-page":"56","DOI":"10.4161\/cc.6.1.3668","article-title":"The role of VHL in the regulation of E-cadherin: a new connection in an old pathway","volume":"6","author":"Russell","year":"2007","journal-title":"Cell Cycle"},{"key":"10.1016\/j.canlet.2012.05.003_b0130","doi-asserted-by":"crossref","first-page":"7052","DOI":"10.1158\/0008-5472.CAN-05-0917","article-title":"Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition","volume":"65","author":"Sun","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2012.05.003_b0135","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O\u2019Reilly","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2012.05.003_b0140","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1038\/leu.2008.243","article-title":"Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells","volume":"22","author":"Nishioka","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2012.05.003_b0145","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1002\/jcb.23123","article-title":"The mouse RANKL gene locus is defined by a broad pattern of histone H4 acetylation and regulated through distinct distal enhancers","volume":"112","author":"Martowicz","year":"2011","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.canlet.2012.05.003_b0150","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1089\/dna.2005.24.209","article-title":"Synergy between deacetylase inhibitors and IL-1beta in activation of the serum amyloid A2 gene promoter","volume":"24","author":"Blais","year":"2005","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.canlet.2012.05.003_b0155","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.bbrc.2010.12.081","article-title":"Involvement of HDAC1 in E-cadherin expression in prostate cancer cells; its implication for cell motility and invasion","volume":"404","author":"Kim","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.canlet.2012.05.003_b0160","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/sj.bjc.6603914","article-title":"The histone deacetylase inhibitor trichostatin A downregulates human MDR1 (ABCB1) gene expression by a transcription-dependent mechanism in a drug-resistant small cell lung carcinoma cell line model","volume":"97","author":"El-Khoury","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2012.05.003_b0165","first-page":"3945","article-title":"Loss of retinoic acid receptor beta gene expression is linked to aberrant histone H3 acetylation in lung cancer cell lines","volume":"62","author":"Suh","year":"2002","journal-title":"Cancer Res."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383512002856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383512002856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T15:27:59Z","timestamp":1542986879000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383512002856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S0304383512002856"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2012.05.003","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}